Keywords: Multiple sclerosis, Novartis, Gilenya, Decision Resources, DMAs, MS

Novartis’ Gilenya has begun to impact established DMAs and market perceptions; report

Article | 01 July 2011

Print This

While physician trialing of Swiss drug major Novartis’ (NOVN: VX) Gilenya (fingolimod), the first oral disease-modifying agent (DMA) for ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in